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Abstract
Background: Semiquantitative methods such as the standardized uptake value ratio (SUVR) require normalization
of the radiotracer activity to a reference tissue to monitor changes in the accumulation of amyloid-β (Aβ) plaques
measured with positron emission tomography (PET). The objective of this study was to evaluate the effect of
reference tissue normalization in a test–retest 18F-florbetapir SUVR study using cerebellar gray matter, white matter
(two different segmentation masks), brainstem, and corpus callosum as reference regions.
Methods: We calculated the correlation between 18F-florbetapir PET and concurrent cerebrospinal fluid (CSF)
Aβ1–42 levels in a late mild cognitive impairment cohort with longitudinal PET and CSF data over the course of
2 years. In addition to conventional SUVR analysis using mean and median values of normalized brain radiotracer
activity, we investigated a new image analysis technique—the weighted two-point correlation function (wS2)—to
capture potentially more subtle changes in Aβ-PET data.
Results: Compared with the SUVRs normalized to cerebellar gray matter, all cerebral-to-white matter normalization
schemes resulted in a higher inverse correlation between PET and CSF Aβ1–42, while the brainstem normalization gave
the best results (high and most stable correlation). Compared with the SUVR mean and median values, the wS2 values
were associated with the lowest coefficient of variation and highest inverse correlation to CSF Aβ1–42 levels across all
time points and reference regions, including the cerebellar gray matter.
Conclusions: The selection of reference tissue for normalization and the choice of image analysis method can affect
changes in cortical 18F-florbetapir uptake in longitudinal studies.
Background
Amyloid-β (Aβ) plaques and neurofibrillary tau tangles
are known pathological features of Alzheimer’s disease
(AD) [1, 2] that manifest years before the onset of clinical
symptoms [3–8]. Aβ plaques are identified in vivo using
brain positron emission tomography (PET) with several
radiotracers, including 11C-Pittsburgh Compound B
(11C-PiB) [9], 18F-florbetapir [10], 18F-FDDNP [11], 18F-
florbetaben [12], and 18F-flutemetamol [13]. The standardized
uptake value ratio (SUVR) is a semiquantitative method
frequently used in clinical trials of antiamyloid drugs to
monitor the accumulation and progression of Aβ pla-
ques and to assess the effects of antiamyloid drug ther-
apy. The SUVR method is used in most large studies
because it is easily calculated and does not require long
dynamic scans or measurement of the arterial input
function. Nevertheless, it requires normalization of re-
gional PET activity to a reference tissue to account for
nonspecific radiotracer binding. Because 11C-PiB and
18F-florbetapir target predominately the classic core and
neuritic Aβ plaques, which are not evidenced in the cere-
bellum [14–17], whole cerebellum (or the cerebellar gray
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matter) is commonly used as a reference region [18, 19].
However, recent research raises new concerns about
the accuracy of the SUVR measures using cerebellar
normalization. In particular, the variability observed in
the longitudinal progression of SUVR values seems to
be discrepant with the expected values on the basis of
pathological and biological grounds.
In recent studies [20–23], researchers have examined
the feasibility of alternative reference regions for amyloid-
PET. Brendel and colleagues [20] used the discriminatory
power between AD, mild cognitive impairment (MCI),
and healthy control (HC) subject groups, as well as the
magnitude and variability of temporal changes in 18F-
florbetapir PET, to evaluate different reference tissue.
Chen and colleagues [21] examined the strength of as-
sociations between 18F-florbetapir PET increase and
clinical decline in addition to means of tracking the
magnitude and variability of longitudinal Aβ-PET changes
in different subject groups. Landau and colleagues [22]
stratified the following subject groups on the basis of their
cerebrospinal fluid (CSF) Aβ1–42 levels at baseline: (1) a
control group that included healthy subjects with normal
and stable CSF Aβ1–42 levels and (2) a second group that
included both cognitively healthy subjects and those with
early amnestic MCI with abnormal CSF Aβ1–42 levels at
baseline. The study was designed to test if the cortical
Aβ-PET levels in the HC group remained stable while
they increased in the second group. All three of these
studies incorporated static 18F-florbetapir PET scans
(summarized in Table 1). In another study, by Wong
and colleagues [23], the distribution volume ratio in a
dynamic 18F-FDDNP PET scan was used to determine
the discriminatory power between an HC group and
the AD group. In all of these studies, researchers found
that use of white matter normalization improved the
accuracy of longitudinal Aβ-PET data more strongly
than use of gray matter normalization.
The objective of our present work was to complement
the previous research by the use of a new PET image
analytical method as well as longitudinal data of both
CSF Aβ1–42 levels and
18F-florbetapir images to identify
which reference region normalization results in the op-
timal visit-to-visit correlation between these two bio-
markers of AD pathology. The subjects in this study
were those diagnosed with late mild cognitive impairment
(LMCI) from the ADNI 2 phase of the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) with stable CSF
Aβ1–42 levels at baseline and at 24-month follow-up;
thus, longitudinal changes in 18F-florbetapir PET were
not expected to occur, which allows use of their PET
images as a test–retest dataset to evaluate the effect of
reference region normalization. All PET images are an-
alyzed with the conventional SUVR mean and median
measures and with a new PET image cluster analysis
tool based on a weighted two-point correlation (wS2).
The wS2 method is a statistical tool adopted from as-
tronomy and materials science and can be used to de-
tect specific changes in spatial patterns within Aβ-PET
images that we refer to as increased clustering or floccu-
lence. Our preliminary data [24] indicate the potential
utility of this method for detecting longitudinal changes
that are difficult to assess with conventional regional
mean image values, which typically have large standard
deviations.
Table 1 Summary of previous longitudinal 18F-florbetapir PET studies for comparison between reference tissues for normalization of
PET activity
Brendel et al. [20] Chen et al. [21] Landau et al. [22]
Reference
regions
Whole cerebellum Whole cerebellum Cerebellar gray matter
Brainstem Pons Whole cerebellum
White matter White matter White matter
Brainstem/pons
Composite ROI
Subject groups MCI (n = 483) MCI (n = 187) CSF- (14)
AD (n = 163) AD (n = 31) CSF+ (n = 91)
HC (n = 316) HC (n = 114)
PET radiotracer 18F-florbetapir 18F-florbetapir 18F-florbetapir
Image analysis Mean SUV/SUVR Mean SUVR Mean SUVR
Evaluation
method
Discrimination power between subject groups, variability
in longitudinal increase in Aβ-PET
Longitudinal increase in Aβ-PET and





White matter/brainstem with partial
volume correction
White matter Reference regions containing
white matter
Aβ amyloid-β, AD Alzheimer’s disease, CSF cerebrospinal fluid, HC healthy controls, MCI mild cognitive impairment, PET positron emission tomography, ROI region
of interest, SUV standardized uptake value, SUVR standardized uptake value ratio
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Methods
Alzheimer’s Disease Neuroimaging Initiative
Data used in the preparation of this article were ob-
tained from the ADNI database (adni.loni.usc.edu). The
ADNI was launched in 2003 as a public-private partner-
ship led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging (MRI), PET, other
biological markers, and clinical and neuropsychological
assessments can be combined to measure the progres-
sion of MCI and early AD.
Subject selection
Data from 21 ADNI subjects with LMCI were used in
our study. We included all subjects with LMCI who had
18F-florbetapir PET and T1-weighted MRI images at
baseline and 24-month follow-up scans following the
PET technical procedures of the ADNI 2 phase. We fur-
ther limited our subject selection to patients with LMCI
who had longitudinal CSF data obtained at time points
close to their PET baseline and follow-up scans. The
specific selection of the LMCI subject group from the
ADNI 2 phase was based on their stable levels of CSF
Aβ1–42, which allowed use of their corresponding longi-
tudinal PET images as a test–retest dataset. While our
selection criteria limited the number of available sub-
jects, one of the main advantages of using the ADNI 2
data was the commonality of the image acquisition pro-
tocols, which ensured consistency of data within and be-
tween sites and thus reduced heterogeneity that would
have otherwise added to the variability of both longitu-
dinal and cross-sectional data. The biomarker datasheet
containing the CSF Aβ1–42 levels was downloaded from
the ADNI archive. The dataset is named UPENN–CSF
Biomarkers [ADNI GO/2] version 2013-10-31.
Table 2 summarizes the demographic information of
the subjects enrolled in this study. Both the baseline and
follow-up Aβ1–42 CSF values (measured as picograms
per milliliter) matched the average ADNI values of the
MCI cohort (baseline 165 ± 45 pg/ml, 24 months 161 ±
46 pg/ml). There was no significant change in CSF Aβ1–
42 levels between baseline and follow-up among these
subjects. This was determined on the basis of the coeffi-
cient of variation of CSF values between the two time
points, which was on average 3.34 % across our cohort.
For comparison, the longitudinal within-laboratory coef-
ficient of variation for CSF measures is typically 5–19 %
[25]. In addition to the CSF values, our subjects’ cogni-
tive test scores, measured using the Alzheimer’s Disease
Assessment Scale–Cognitive subscale (ADAS-cog) [26],
were 18 ± 7 at baseline and 19 ± 10 at follow-up. The
Clinical Dementia Rating scores at both baseline and
24 months were 0.5 for almost all subjects. The Mini
Mental State Examination (MMSE) [27] scores were 28 ±
2 at baseline and 26 ± 3 at follow-up. To summarize the
subjects’ clinical status, we included the box plots of their
ADNI composite memory score [28], which combines the
Rey Auditory Verbal Learning Test, the Logical Memory
Test of the Wechsler Memory Scale, the MMSE, and the
ADAS-cog (Fig. 1).
Data acquisition, image reconstruction, and preprocessing
All patient data were acquired at participating ADNI sites.
18F-florbetapir PET, together with concurrent T1-weighted
MRI volumes at baseline and 24-months follow-up, were
downloaded from the ADNI database. The detailed de-
scription of the acquisition protocol can also be found on
the ADNI website (http://adni.loni.usc.edu/). According to
the ADNI protocols, a 370-MBq bolus injection of radio-
tracer was administered. This was followed by a 20-minute
continuous brain PET imaging session that began ap-
proximately 50 minutes after the injection. The images
were reconstructed immediately after the 20-minute scan
according to scanner-specific reconstruction protocols, each
using different versions of a maximum likelihood algorithm,
to assess the scan quality and potential presence of motion
artifacts. All images were corrected for attenuation and scat-
ter according to the scanner-specific protocols. Upon com-
pletion, the imaging data were uploaded to the data archive
of the Laboratory of Neuro Imaging at the University of
Southern California, where they were coregistered and aver-
aged. These are the datasets used in this study.
Image analysis
18F-florbetapir images of each subject were aligned to
their concurrent T1-weighted MRI volume. Gray matter
and white matter masks of the T1-weighted MRI volumes





Baseline age, yr 73 ± 8
APOE A1/A2 carriers, n 9
Time between PET scan and CSF, days 6 ± 14
CSF Aβ1–42, pg/ml 165 ± 45 (baseline) and 161 ± 46
(follow-up)
ADAS-cog score 18 ± 7 (baseline) and 19 ± 10
(follow-up)
Clinical Dementia Rating score 0.5 ± 0 (baseline) and 0.5 ± 0.3
(follow-up)
Mini Mental State Examination score 28 ± 2 (baseline) and 26 ± 3
(follow-up)
Aβ, Amyloid-β; ADAS-cog, Alzheimer’s Disease Assessment Scale–Cognitive
subscale; ADNI, Alzheimer’s Disease Neuroimaging Initiative; APOE, apolipoprotein
E; CSF, cerebrospinal fluid; PET, positron emission tomography. Data type in this
table are number, age, days, CSF levels and results of the test scores
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were segmented in each subject’s native space using
SPM12 software (Wellcome Trust Centre for Neuroimag-
ing, London, UK). Two different thresholds were applied
on the segmented white matter to generate two types of
white matter masks. The 10 % white matter mask included
white matter voxels that were adjacent to gray matter.
These border voxels were removed in the 100 % white matter
mask. The template-based regional masks from the cerebellar
gray matter and brainstem were obtained from the SPM12
atlas (labels_Neuromorphometrics.nii) and deformed into the
subject’s native space. Regional masks for the corpus callosum
were drawn manually. This was done by importing the MRI
volumes into Amide, a medical image display and data ana-
lysis tool [29], where the center slice of the sagittal view was
used to draw a region of interest around the splenium of the
corpus callosum. Figure 2 represents candidate reference re-
gions overlaid on a subject’s T1-weighted MRI scan. The
cerebral brain gray matter PET signal was normalized with
respect to each mask, and the SUVR mean and median
values were calculated.
In addition to the SUVR mean and median values, we
also calculated the wS2 of the florbetapir PET images.
The wS2 method is a statistical image analytical method
commonly used in astronomy [30] and materials science
[31]. With this method, we derived a quantitative param-
eter from PET images to characterize the heterogeneity
of the Aβ-PET activity distribution, which we refer to as
the clustering or flocculence. The wS2 analysis was also
implemented with normalized Aβ-PET images. However,
unlike the regional mean and median values, changes in
wS2 more specifically reflect changes in the spatial pat-
terns of activity. Thus, these changes are potentially less
sensitive to minor temporal variations in the reference
tissue activity (variations in normalization threshold). PET
analysis using the wS2 method also results in smaller
standard errors and thus may be more suitable for de-
tecting subtle changes due to the larger effect size. The
theoretical framework of wS2 is described in our previous
work where this method was validated with 11C-PiB PET
data [24].
The calculation of wS2 started with sampling 50,000
random voxel pairs located within the gray matter of the
18F-florbetapir PET image volume. For each voxel pair
(each sampling instance), a weighting factor was calculated
as the product of two terms. The first term was the average
value of the two voxels, and the second term incorporated
the absolute difference between the two voxel values into
an exponential term. The weighting factor of an instance is
higher when the values of both voxels are high and these
values are close to each other. All sampling instances were
then binned by the intervoxel distances, and for a given
distance r the sum of the weighting factors was divided by
the total number of instances with distance r and plotted
versus r to obtain a wS2 between 0 and 10 mm. Both the
slope and the wS2 area under the curve (AUC) change with
the increased activity and increased heterogeneity of the
activity distribution within the brain. Figure 3 shows the
wS2 AUCs from two florbetapir PET images. The wS2
AUC was used as the quantitative outcome of this analysis
and was calculated together with the mean and median
of the SUVR for all baseline and follow-up images. The
coefficients of variation of SUVR mean and median, as
well as wS2 across different time points and normalization
schemes, were calculated over all 21 participants. Spear-
man’s rank correlation coefficient was calculated between
the 18F-florbetapir PET outcomes (SUVR mean and
median and ws2) and the CSF Aβ1–42 at baseline and
follow-up.
Fig. 1 Box plots of the Alzheimer’s Disease Neuroimaging Initiative composite memory score (ADNI-MEM), combining the Rey Auditory
Verbal Learning Test, the Logical Memory Test of the Wechsler Memory Scale, the Mini Mental State Examination and the Alzheimer’s Disease
Assessment Scale–Cognitive subscale
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Results
We used five different normalization regions (Fig. 2) to
evaluate the correlation between amyloid-PET and CSF
measures in a test–retest study. This association is graph-
ically illustrated for all subjects at baseline and follow-up
in Fig. 4 (cerebellar gray matter), Fig. 5 (10 % white mat-
ter), Fig. 6 (100 % white matter), Fig. 7 (brainstem), and
Fig. 8 (corpus callosum). The medium and mean SUVR
values and the wS2 AUC were plotted (x-axis) versus the
CSF Aβ1–42 (y-axis). For each subject, the baseline marker
(black) was connected via a line to the follow-up marker
(red) to show each subject’s individual change. Qualita-
tively, the scatterplot of SUVR mean and median values
versus CSF Aβ1–42 showed the lowest linear association
between the two biomarkers when the cerebellar gray
matter was selected as the reference region (Fig. 4a and
b). With cerebellar normalization, the global mean and
median SUVR values were between 1.1 and 2.0. The
CSF Aβ1–42 of brains with mean and median SUVR less
than 1.5 seemed to remain clustered around 200 pg/ml,
whereas SUVR mean and median values greater than
1.5 were associated with CSF Aβ1–42 values around
125 pg/ml. The scatterplots of the wS2 outcomes
showed a more linear association with CSF Aβ1–42 for
all normalization schemes including the cerebellar gray
matter (Fig. 4.C). This association was quantitatively
evaluated by using Spearman’s rank correlation coefficient
(Fig. 9, Table 3) between the two biomarkers at both base-
line (black bar) and follow-up (red bar). While the cor-
relation was statistically significant for all normalization
schemes, time points and methods of analysis, it was
modest (~0.5) when cerebellar gray matter was selected
as reference tissue and the SUVR mean and median
values were calculated for PET analysis. The brainstem
normalization resulted in the highest and most stable
(lowest variability) Spearman’s rank correlation values
(~0.8) across both time points and all three methods of
analysis. The coefficient of variation across all time points
and normalization schemes was 0.10 for wS2 method, 0.14
for SUVR mean and 0.13 for SUVR median.
Discussion
The results of this study show that analysis of
18F-florbetapir PET data normalized to white matter
Fig. 2 Reference tissue masks. Cerebellar gray matter (a), 100 % threshold white matter mask (b), 10 % threshold white matter mask (c) ,
brainstem (d), and splenium of corpus callosum (e)
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reference regions results in a higher inverse correl-
ation to CSF Aβ1–42 and that this correlation exhibits
less variability over time compared with 18F-florbetapir
PET data that are normalized to cerebellar gray matter
(Table 3, Fig. 9). These findings are in agreement with
recent studies [20–23] in which researchers investigated
the effect of reference tissue normalization using a
Fig. 3 18F-florbetapir positron emission tomographic images
(zoomed over an axial slice located in the frontal lobe) from two
subjects (a) with low tracer uptake and (b) with high tracer uptake,
as well as (c) the weighted two-point correlation function (wS2)
calculated from whole-brain images of these two subjects
Fig. 4 Scatterplots of all cerebrospinal fluid (CSF) amyloid-β1–42
(Aβ1–42) versus standardized uptake value ratio (SUVR) median (a),
mean (b), and weighted two-point correlation function (wS2) (c)
values obtained by normalization of positron emission tomography
activity to cerebellar gray matter at baseline (black dots) and 24-month
follow-up (red dots)
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significantly larger number of ADNI subjects. This
good agreement despite a smaller cohort in our study
could be partially attributed to our subject selection,
which consisted of ADNI2 patients with LMCI. As
described in the Methods section, the image acquisi-
tion protocols of ADNI 2 were designed to ensure
consistency of data within and between sites. All our
subjects had 18F-florbetapir PET scans at baseline and
24-month follow-up using the same (within-subject)
scanner and the same image reconstruction and correc-
tion methods. These factors may have helped to reduce
potential heterogeneities within this cohort that would
Fig. 5 Scatterplots of all cerebrospinal fluid (CSF) amyloid-β1–42
(Aβ1–42) versus standardized uptake value ratio (SUVR) median (a),
mean (b), and weighted two-point correlation function (wS2) (c)
values obtained by normalization of positron emission tomography
activity to white matter (10 %) at baseline (black dots) and 24-month
follow-up (red dots)
Fig. 6 Scatterplots of all cerebrospinal fluid (CSF) amyloid-β1–42
(Aβ1–42) versus standardized uptake value ratio (SUVR) median (a),
mean (b), and weighted two-point correlation function (wS2) (c)
values obtained by normalization of positron emission tomography
activity to white matter (100 %) at baseline (black dots) and 24-month
follow-up (red dots)
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otherwise have added to variability in both longitudinal
and cross-sectional data.
Another advantage of ADNI 2 is the availability of
concurrent CSF Aβ1–42 at both baseline and 24-month
follow-up time points, which allowed us to use them as
a reference method to correlate with PET data at two
different time points. On the basis of their stable CSF
Aβ1–42, the brain amyloid levels of these subjects were
not expected to change between baseline and the 24-month
follow-up PET scans, thus making the 18F-florbetapir PET
images from this cohort an appropriate dataset for
test–retest variability assessment of reference region
normalization. The observed stable CSF Aβ1–42 was not
unexpected for subjects with LMCI, because it is known
Fig. 7 Scatterplots of all cerebrospinal fluid (CSF) amyloid-β1–42
(Aβ1–42) versus standardized uptake value ratio (SUVR) median (a),
mean (b), and weighted two-point correlation function (wS2) (c)
values obtained by normalization of positron emission tomography
activity to brainstem at baseline (black dots) and 24 months follow-up
(red dots)
Fig. 8 Scatterplots of all cerebrospinal fluid (CSF) amyloid-β1–42
(Aβ1–42) versus standardized uptake value ratio (SUVR) median (a),
mean (b), and weighted two-point correlation function (wS2) (c)
values obtained by normalization of positron emission tomography
activity to corpus callosum at baseline (black dots) and 24-month
follow-up (red dots)
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that the biomarkers of amyloid deposition approach a
plateau by the onset time of LMCI and clinical AD [30].
Using a cohort with stable CSF Aβ1–42, our objective
was to find a reference tissue that would give the highest
and most stability (lowest variability) in Spearman’s rank
correlation between these two biomarkers calculated at
two time points. While all white matter–normalized
SUVRs indicated higher correlation to CSF measures than
the cerebellar normalization, the brainstem normalization
gave the best results among the white matter regions des-
pite its location at the edge of the PET scanner field of
view (FOV). The location of the cerebellum was suspected
Fig. 9 Spearman’s rank correlation between cerebrospinal fluid (CSF) amyloid-β1–42 (Aβ1–42) and
18F-florbetapir standardized uptake value ratio
(SUVR) median and mean and weighted two-point correlation function (wS2) measures at baseline (black bars) and 24-month follow-up (red bars)
for five different reference tissue normalization schemes
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to be the main reason for variability observed in the previ-
ous studies [21, 22]. Due to their location, both brainstem
and cerebellum are subject to increased scatter and de-
creased geometric sensitivity. However, PET data undergo
rigorous attenuation, scatter, and normalization correc-
tions to ensure uniformity within the FOV. Also, given
that in our study the correlation values for cerebellar
normalization were at their lowest levels for both baseline
and follow-up time points, other factors, such as biological
effects, could be more relevant than scanner-related phys-
ical effects. The connecting lines in Fig. 4 show that the
within-subject differences between baseline and follow-up
PET data (mainly intermediate SUVR mean and median
values) were larger than all other normalization schemes
(Figs. 5, 6, 7 and 8). In these figures, it is also apparent that
the association between all three PET analytical methods
and CSF measures become increasingly nonlinear as the
PET values increase. This nonlinearity effect was most
prominent when cerebellar gray matter was used as ref-
erence tissue (Fig. 4), where the CSF data of SUVR
mean and median values below 1.5 were clustered around
200 pg/ml and the CSF data of SUVR mean and median
values above 1.5 corresponded to CSF measures that
remained around 125 pg/ml. All other white matter
normalization schemes resulted in slightly more linear
associations with CSF measures, in particular for inter-
mediate PET values.
We included CSF because Aβ accumulation has been
hypothesized to result from an imbalance between Aβ
production and clearance [2, 32–35]. In particular, the
impairment of clearance mechanisms seems to be the
main cause of Aβ accumulation in sporadic or late-onset
forms of AD [35], which account for the majority of pa-
tients with AD. In several previous studies, researchers
have observed a relationship between cortical amyloid
tracer binding and levels of CSF Aβ1–42 using
11C-PiB
[36] and 18F-florbetapir [37]. These studies, which were
based on cerebellar normalization, showed that the CSF
levels decreased with increased radiotracer uptake but
reached a plateau at higher SUVR values. We made a
similar observation with cerebellum normalization (Fig. 4a
and b). Other reference region normalizations, the brain-
stem in particular, resulted in more linear relationships
across a wide range of cortical radiotracer uptake values
at both baseline and follow-up. We emphasize on the
importance of this observation because the axial location
of the cerebellum (increased scatter and attenuation)
accounted for the observed longitudinal variabilities in
previous studies. However, scanner-related effects would
affect the PET–CSF association within the whole spectrum
of SUVR values. Also, both the brainstem and the cerebel-
lum are equally subject to increased scatter and decreased
geometric sensitivity. Our approach might indicate that
the variability associated with the reference region
normalization may more likely be related to biological
factors than to scanner-related effects.
Four different white matter masks (white matter 10 %,
white matter 100 %, brainstem, and splenium of corpus
callosum) were applied. While the white matter 10 %
included the white matter regions that shared borders
with gray matter, these regions were removed in the
100 % white matter mask. Correlation values from these
two white matter masks and the corpus callosum were
similar.
The wS2 technique was used as an additional method
complementary to the conventional SUVR analysis that
is performed by calculating regional mean and median
SUVR values. Compared with the SUVR mean and me-
dian values, the wS2 metric was associated with the high-
est average Spearman’s rank correlation across all time
points and reference regions, including the cerebellar gray
matter. Given that the wS2 metric is based on changes
in image spatial patterns, we expected that this method
would be slightly less sensitive to minor temporal varia-
tions in reference region radiotracer activity, which would
cause variations in normalization thresholds. The wS2
method evaluates associations between voxel values at
different distances. These associations remain preserved,
to some extent, even when the normalization threshold
varies.
To date, we have applied the wS2 analysis with two dif-
ferent radiotracers (11C-PiB and 18F-florbetapir) and have
been able to show consistent results. Using a statistical
analysis, we evaluated the effect of injected dose (as a
surrogate for image noise) and the region size on the
wS2 outcomes and made a comparison with SUVR
Table 3 Spearman’s rank correlation between CSF Aβ1–42 and PET measures
Baseline Follow-up
SUVR median SUVR mean wS2 SUVR median SUVR mean wS2
Cerebellum 0.51 0.51 0.69 0.67 0.66 0.74
White matter (10 %) 0.81 0.85 0.89 0.74 0.77 0.73
White matter (100 %) 0.85 0.86 0.91 0.77 0.79 0.74
Brainstem 0.79 0.79 0.85 0.81 0.83 0.85
Corpus callosum 0.8 0.81 0.85 0.68 0.69 0.72
SUVR standardized uptake value ratio; wS2 weighted two-point correlation function
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mean and median values. We obtained high and stable
correlations between CSF Aβ levels and wS2 outcomes
with both radiotracers. Further validations would require
a full quantitative analysis using kinetic modeling and
dynamic acquisitions. Our main future objective is to
test the wS2 methodology with dynamic PET scans and
list-mode data acquisition to investigate how different
image acquisition (starting time point and duration) and
reconstruction parameters (number of iterations and noise
regularization) can change the image spatial patterns
and subsequently the wS2 outcomes. Image preprocessing
is another important factor. Spatial resolutions of human
PET scanners range from greater than 2.5-mm full-width
half-maximum (FWHM) in some research scanners to
greater than 7-mm FWHM in many commonly used clin-
ical PET systems [38–40]. Additional preprocessing steps,
such as image smoothing, further reduce the image reso-
lution from 7- to 12-mm FWHM. For example, most re-
ported ADNI analyses use level 4 preprocessed imaging
data, which are smoothed to a uniform isotropic reso-
lution of 8-mm FWHM [39]. The smoothing process is
beneficial for cross-sectional comparisons and for qualita-
tive visual reads by clinicians, due to the improved uni-
formity. However, it has a disadvantage in that potentially
important high-resolution spatial patterns are smoothed
away [40]. The spatial smoothing of within-subject longi-
tudinal can reduce the effect size [41]. We are the first
group, to our knowledge, to propose a method designed
to improve understanding of the nature of nonuniform
spatial activity patterns that explain the impact of spatial
smoothing on longitudinal changes.
Conclusions
The selection of reference tissue for normalization of
18F-florbetapir PET images as well as the image analysis
method can modify the quantitative outcomes in longi-
tudinal studies. Understanding factors that contribute to
temporal variations of reference region radiotracer up-
take merits further investigation.
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